26S proteasome Inhibitors
1 drugsAbout 26S proteasome
The 26S proteasome is a large protein complex responsible for degrading damaged or unnecessary proteins, maintaining cellular homeostasis. Its proteolytic function makes it a valuable drug target, particularly in oncology, by disrupting protein degradation and inducing cell death.
Inhibiting the 26S proteasome disrupts protein degradation, leading to an accumulation of misfolded proteins and cell death, especially in cancer cells. Currently, there is no genetic evidence data available linking the 26S proteasome to specific diseases.
There is one FDA-approved drug, VELCADE (Takeda), a small molecule targeting the 26S proteasome for oncology indications. VELCADE was first approved in 2003 and remains the only approved drug for this target.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
- White space opportunity in Multiple Myeloma (MM) with only 2 trials.
- phase1 represents biological uncertainty with 53% completion.
Top 26S proteasome Drugs
Takeda is the only company with an approved drug targeting the 26S proteasome.
The market is highly concentrated, suggesting high entry barriers or limited commercial opportunity.
26S proteasome Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 26S proteasome, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
26S proteasome Clinical Trials 506 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 153 | 90 | 38 | 25 | 70% |
| Phase 2 | 248 | 121 | 63 | 64 | 66% |
| Phase 3 | 91 | 38 | 6 | 47 | 86% |
| Phase 4 | 14 | 6 | 4 | 4 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved 26S proteasome drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting 26S proteasome. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
26S proteasome Drug Approval Timeline (2003 - 2003)
VELCADE was approved in 2003 and remains the only approved drug.
The approval timeline suggests potential saturation or challenges in developing new drugs for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 225 clinical trials targeting 26S proteasome.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities